Pages that link to "Q24612429"
Jump to navigation
Jump to search
The following pages link to Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma (Q24612429):
Displaying 50 items.
- GSVD comparison of patient-matched normal and tumor aCGH profiles reveals global copy-number alterations predicting glioblastoma multiforme survival (Q21090956) (← links)
- A user's guide to the encyclopedia of DNA elements (ENCODE) (Q21092716) (← links)
- MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma (Q21261286) (← links)
- Genome-wide association study of glioma and meta-analysis (Q23919638) (← links)
- Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease (Q24289344) (← links)
- KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas (Q24307815) (← links)
- The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers (Q24339485) (← links)
- IDH1 and IDH2 mutations in gliomas (Q24561928) (← links)
- NPAS3 demonstrates features of a tumor suppressive role in driving the progression of Astrocytomas (Q24604657) (← links)
- Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas (Q24610836) (← links)
- A decade of exploring the cancer epigenome - biological and translational implications (Q24614467) (← links)
- Molecular subgroups of medulloblastoma: the current consensus (Q24615271) (← links)
- Links between metabolism and cancer (Q24626229) (← links)
- DNA methylation screening identifies driver epigenetic events of cancer cell survival (Q24632287) (← links)
- Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases (Q24632807) (← links)
- Recent advances in the molecular understanding of glioblastoma (Q24632928) (← links)
- DNA repair mechanisms and their clinical impact in glioblastoma (Q26740256) (← links)
- Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives (Q26744441) (← links)
- Advances in the treatment of newly diagnosed glioblastoma (Q26773514) (← links)
- In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies (Q26820289) (← links)
- Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date (Q26822717) (← links)
- Cancer heterogeneity--a multifaceted view (Q26829228) (← links)
- NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age (Q26830388) (← links)
- Epigenomics of cancer - emerging new concepts (Q26830534) (← links)
- O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems (Q26853112) (← links)
- Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods (Q26853516) (← links)
- Molecular characteristics of pediatric high-grade gliomas (Q26860786) (← links)
- New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma (Q26863394) (← links)
- Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors (Q26864920) (← links)
- IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma (Q26995506) (← links)
- Oligodendroglioma: pathology, molecular mechanisms and markers (Q27002448) (← links)
- Brain tumor stem cells: Molecular characteristics and their impact on therapy (Q27003138) (← links)
- Emerging patterns of somatic mutations in cancer (Q27014126) (← links)
- Evolution of the cancer genome (Q27020991) (← links)
- Developing epigenetic diagnostics and therapeutics for brain disorders (Q27022987) (← links)
- An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma (Q27024830) (← links)
- Contemporary murine models in preclinical astrocytoma drug development (Q27026937) (← links)
- Connexin 30 expression inhibits growth of human malignant gliomas but protects them against radiation therapy (Q27322751) (← links)
- IDH mutations in tumorigenesis and their potential role as novel therapeutic targets (Q27692015) (← links)
- An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. (Q27852141) (← links)
- ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis (Q27852494) (← links)
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas (Q27853175) (← links)
- IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives (Q28066926) (← links)
- Role of TET enzymes in DNA methylation, development, and cancer (Q28068541) (← links)
- Epigenetic Therapeutics: A New Weapon in the War Against Cancer (Q28072370) (← links)
- The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis (Q28074595) (← links)
- The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation (Q28075374) (← links)
- Genome-wide epigenomic profiling for biomarker discovery (Q28080102) (← links)
- Oncometabolites: tailoring our genes (Q28085392) (← links)
- Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer (Q28087759) (← links)